Content intended for health care professionals.

Assess different patient scenarios and review guideline recommendations

Patient Profiles

Impact of intolerance on patient goals

Patient profile of Quinn who’s persistent AE has become intolerable.

Patient portrayal.

Quinn is a mother of 3 and is constantly in motion. While achieving a durable response from her CML treatment, she deals with an ongoing AE that disrupts her active lifestyle.

Quinn has noted that her persistent AE has become intolerable, and is experiencing fatigue that is slowing her down and not allowing her to keep up with her kids’ extracurricular activities. How would that influence your clinical assessment?

    Sokal Risk Score
  • Low risk (0.7)
    Time Since Diagnosis
  • 36 months
    Current Treatment
  • 2nd-line TKI
    Length of Time on Current Treatment
  • 12 Months
    Molecular Status
  • 0.5% BCR-ABL1
    Persistent AEs
  • Grade 2 fatigue
According to the National Comprehensive Cancer Network® (NCCN®), patients with >0.1% to 1% BCR-ABL1 at 12 months have TKI-sensitive disease and patient goals may influence clinical considerations1
Patient Video

Get different perspectives from patients with CML

Clock 4 min 28 second watch

See what patients in later lines have to say about their experience with CML, including challenges they faced, how they overcame them, and what advice they have to share.

AEs, adverse events; CML, chronic myeloid leukemia.

Review videos from CML experts, patients, and more.

Watch now

ATP, adenosine 5’-triphosphate; CML, chronic myeloid leukemia; NCCN, National Comprehensive Cancer Network; TKI, tyrosine kinase inhibitor.

Reference: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed May 4, 2023. To view the most recent and complete version of the guidelines, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

arrow topBack to top